Loading quotes...

Forecast

The analysts' average price target is €28.54 (+309.47%). The median is €30.74 (+341.03%).

Buy	6
Hold	3
Sell	1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Avalo Therapeutics draws Buy rating and $35 target from BofA after positive Phase 2 HS data

Bank of America started coverage of Avalo Therapeutics with a Buy rating and $35 price target, citing positive Phase 2 results for lead candidate abdakibart in hidradenitis suppurativa and a differentiated IL‑1β antibody profile. BofA highlights a convenient monthly dosing potential, a large undertreated market, and a balance sheet runway into 2029 after about $405M net proceeds. Avalo's one‑year stock performance has outpaced the market markedly and analyst coverage shows substantial upside potential, though the article notes alternative picks may offer different risk/reward profiles. » More on finance.yahoo.com
Avalo Therapeutics rises about 35% after positive phase‑2 data on Abdakibart

Avalo Therapeutics’ shares jumped about 35% in after‑hours trading following positive topline results from the phase‑2 LOTUS study of Abdakibart in moderate to severe hidradenitis suppurativa. Both tested doses met the primary endpoint HiSCR75 at week 16 with response rates of 42.2% and 42.9% versus 25.6% for placebo; key secondary endpoints also showed statistically significant benefit. Abdakibart demonstrated a favourable safety profile, and Avalo plans a registrational phase‑3 program and a committed public offering to finance development. » More on de.investing.com

Financials

In the last quarter, AVALO THERAPEUT. DL-,001 had revenue of €0 and net profit of -€16.73M

(EUR)	September 2026	YoY
Revenue	0	-
Gross profit	0	100.00%
Net profit	-16.73M	35.91%
EBITDA	-16.7M	35.85%

Fundamentals

Metric	Value
Market capitalization	€444.85M
Number of shares	57.82M
52-week high/low	€21.94 - €5.90
Dividends	No
Beta	0.75
P/E ratio	-2.94
PEG ratio	0.01
P/B ratio	1.07
P/S ratio	8,340.24

Company profile

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.